II. Looking into the future of platelet transfusion in the presence of P2Y 12 inhibitors

British Journal of Anaesthesia

Volumn 112, Issue 5, 2014, Pages 780-784

  Tanaka, K A ^a   Subramaniam, K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; FIBRINOGEN CONCENTRATE; PRASUGREL; PROTHROMBIN COMPLEX; PURINERGIC P2Y RECEPTOR ANTAGONIST; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE CONCENTRATE; THROMBOXANE; TICAGRELOR;

ALLERGIC REACTION; APHERESIS; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD SAMPLING; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; ELECTRODE; HEART SURGERY; HUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

FORECASTING; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84899875922     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet584     Document Type: Editorial

References (39)

1. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 529-55
2. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-43
3. Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011; 305: 1136-7
4. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8: 2140-8
5. Breet NJ, vanWerkumJW, BoumanHJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62
6. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel basedonplatelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105
7. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-64
8. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-99
9. Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregationandits association with stent thrombosisandbleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-8
10. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-23
11. BenzonHT,McCarthy RJ, BenzonHA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. Br J Anaesth 2011; 107: 966-71
12. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurementbased strategy to reduce bleeding and waiting time in clopidogreltreated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-9
13. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92: 178-86
14. Gö rlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery:aretrospective, single-center cohort study. Anesthesiology 2011; 115: 1179-91
15. Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531-47
16. Hansson E, Shams H, Astrom-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014; 112: 570-5
17. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ. The effects of age and sex onthe disposition of acetylsalicylic acidand its metabolites. Br J Clin Pharmacol 1985; 19: 675-84
18. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-42
19. TengR, Oliver S,Hayes MA,Butler K. Absorption, distribution,metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010; 38: 1514-21
20. HongoRH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231-7
21. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004; 128: 425-31
22. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91: 123-9
23. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007; 5: 82-90
24. Zafar MU, Santos-Gallego C,VorchheimerDA, et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost 2013; 11: 100-6
25. Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 9: 1730-7
26. Prü ller F, Drexler C, Archan S, Macher S, Raggam RB, Mahla E. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study. J Thromb Haemost 2011; 9: 1670-3
27. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326S-50S
28. GogartenW,VandermeulenE,VanAkenH, et al.Regionalanaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999-1015
29. Horlocker TT. Regional anaesthesia in the patient receiving antithromboticandantiplatelet therapy. Br JAnaesth 2011;107(Suppl. 1): i96-106
30. Jakubowski JA, Payne CD,WeerakkodyGJ, et al.Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007; 49: 167-73
31. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-95
32. Hosokawa K, Ohnishi T, Fukasawa M, et al. A microchip flowchamber systemfor quantitativeassessmentof the platelet thrombus formation process. Microvasc Res 2012; 83: 154-61
33. Hosokawa K, Ohnishi T, Sameshima H, et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation underarterialflowconditions. ThrombHaemost 2013;109: 102-11
34. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 1991; 5: 146-54
35. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382
36. GorlingerK,Shore-LessersonL,DirkmannD,HankeAA,Rahe-MeyerN, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013; 27: S20-34
37. Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. Anesth Analg 2011; 113: 703-10
38. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and numberof transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112: I276-80
39. Thiele T, Sumnig A, Hron G, et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012; 10: 968-71